John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EXK
1501
Endeavour Silver
EXK
$3.27B
| $1.41M | ﹤0.01% |
302,841
+284,027
| +1,510% | +$1.24M |
|
1502
ARS Pharmaceuticals
SPRY
$554M
| $1.41M | ﹤0.01% |
401,176
+9,492
| +2% | +$41.3K |
|
1503
HealthStream
HSTM
$844M
| $1.41M | ﹤0.01% |
70,624
+12,115
| +21% | +$274K |
|
|
HSKA
1504
DELISTED
Heska Corp
HSKA
| $1.41M | ﹤0.01% |
10,163
+5,057
| +99% | +$716K |
|
1505
Energy Recovery
ERII
$400M
| $1.4M | ﹤0.01% |
69,532
+51,938
| +295% | +$1.01M |
|
1506
St. Joe Company
JOE
$3.96B
| $1.4M | ﹤0.01% |
+23,561
| New | +$1.22M |
|
1507
PACCAR
PCAR
$68.2B
| $1.4M | ﹤0.01% |
23,768
-671,440
| -97% | -$41M |
|
1508
SPX Corp
SPXC
$10.2B
| $1.39M | ﹤0.01% |
28,163
+3,641
| +15% | +$188K |
|
1509
Stellus Capital Investment Corp
SCM
$249M
| $1.39M | ﹤0.01% |
100,150
-2,228
| -2% | -$30.4K |
|
|
EVOP
1510
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $1.39M | ﹤0.01% |
60,198
+39,998
| +198% | +$951K |
|
1511
Cartesian Therapeutics
RNAC
$322M
| $1.39M | ﹤0.01% |
37,627
-10,916
| -22% | -$683K |
|
|
STEL
1512
DELISTED
Stellar Bancorp
STEL
| $1.39M | ﹤0.01% |
44,765
-17,502
| -28% | -$533K |
|
1513
Teekay Tankers
TNK
$3.11B
| $1.39M | ﹤0.01% |
+100,150
| New | +$1.22M |
|
1514
Xponential Fitness
XPOF
$216M
| $1.39M | ﹤0.01% |
59,068
-15,059
| -20% | -$294K |
|
1515
Nordic American Tanker
NAT
$1.46B
| $1.38M | ﹤0.01% |
+649,680
| New | +$1.15M |
|
1516
Silicon Laboratories
SLAB
$7.28B
| $1.38M | ﹤0.01% |
+9,217
| New | +$1.47M |
|
|
AHT
1517
Ashford Hospitality Trust
AHT
$21.6M
| $1.38M | ﹤0.01% |
13,530
-19,841
| -59% | -$1.77M |
|
|
BELFB
1518
Bel Fuse Inc Class B
BELFB
$3.59B
| $1.38M | ﹤0.01% |
77,122
-475
| -0.6% | -$7K |
|
1519
ICF International
ICFI
$1.59B
| $1.38M | ﹤0.01% |
+14,610
| New | +$1.37M |
|
1520
Adecoagro
AGRO
$1.58B
| $1.37M | ﹤0.01% |
+113,600
| New | +$1.05M |
|
|
PLXP
1521
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $1.37M | ﹤0.01% |
338,832
-86,309
| -20% | -$473K |
|
1522
AZZ Inc
AZZ
$4.18B
| $1.37M | ﹤0.01% |
28,330
+6,796
| +32% | +$337K |
|
1523
Helios Technologies
HLIO
$2.45B
| $1.37M | ﹤0.01% |
+17,038
| New | +$1.36M |
|
|
SEMR
1524
DELISTED
Semrush
SEMR
| $1.37M | ﹤0.01% |
114,496
-52,171
| -31% | -$785K |
|
1525
Omeros
OMER
$1.4B
| $1.36M | ﹤0.01% |
226,787
-321,531
| -59% | -$2.01M |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.